The National Institute for Health and Care Excellence (NICE) issued two final guidelines, recommending Pfizer’s Inlyta (axitinib) in kidney cancer, but rejecting Dendreon’s Provenge (sipuleucel-T) in prostate cancer. In guidance issued to the NHS, the drug pricing watchdog recommended Inlyta as a second-line option for treating adults with advanced renal …